Clyde Markowitz
YOU?
Author Swipe
View article: Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment
Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment Open
Multiple sclerosis is a biologically and clinically heterogenous inflammatory demyelinating disease, driven by relapsing and progressive mechanisms, all individuals experiencing varying degrees of both. Existing highly effective therapies …
View article: Investigating mood and cognition in people with multiple sclerosis: a prospective cross-sectional study protocol
Investigating mood and cognition in people with multiple sclerosis: a prospective cross-sectional study protocol Open
Introduction Multiple sclerosis (MS) is an immune-mediated neurological disorder that affects one million people in the USA. Up to 50% of patients with MS experience depression, yet the mechanisms of depression in MS remain underinvestigat…
View article: Investigating Mood and Cognition in People with Multiple Sclerosis: A Prospective Study Protocol
Investigating Mood and Cognition in People with Multiple Sclerosis: A Prospective Study Protocol Open
Multiple sclerosis (MS) is an immune-mediated neurological disorder that affects one million people in the United States. Up to 50% of people with MS experience depression, yet the mechanisms of depression in MS remain under-investigated. …
View article: Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review
Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review Open
Four sphingosine 1‐phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety…
View article: A Proposed Approach to Screening and Surveillance Labs for Patients With Multiple Sclerosis on Anti-CD20 Therapy
A Proposed Approach to Screening and Surveillance Labs for Patients With Multiple Sclerosis on Anti-CD20 Therapy Open
We propose evidence-based screening and safety surveillance labs which take into account likelihood of changing management in an otherwise stable or asymptomatic individual.
View article: Mapping the Relationship of White Matter Lesions to Depression in Multiple Sclerosis
Mapping the Relationship of White Matter Lesions to Depression in Multiple Sclerosis Open
We demonstrated that lesion location and burden may contribute to depression comorbidity in MS. MS lesions disproportionately impacted fascicles in the depression network. MS+Depression patients had more disease than MS-Depression patients…
View article: Intersite brain MRI volumetric biases persist even in a harmonized multisubject study of multiple sclerosis
Intersite brain MRI volumetric biases persist even in a harmonized multisubject study of multiple sclerosis Open
Background and Purpose Multicenter study designs involving a variety of MRI scanners have become increasingly common. However, these present the issue of biases in image‐based measures due to scanner or site differences. To assess these bi…
View article: Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple Sclerosis
Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple Sclerosis Open
Neuroinvasive WNV infection can develop with anti-CD20 monotherapy in the absence of additional immunosuppression. WNV serologies may be negative in the setting of anti-CD20 treatment; in the appropriate clinical context, one should consid…
View article: Mapping the relationship of white matter lesions to depression in multiple sclerosis
Mapping the relationship of white matter lesions to depression in multiple sclerosis Open
Importance Multiple sclerosis (MS) is an immune-mediated neurological disorder that affects nearly one million people in the United States. Up to 50% of patients with MS experience depression. Objective To investigate how white matter netw…
View article: Inter-scanner brain MRI volumetric biases persist even in a harmonized multi-subject study of multiple sclerosis
Inter-scanner brain MRI volumetric biases persist even in a harmonized multi-subject study of multiple sclerosis Open
Background/Purpose Multicenter study designs involving a variety of MRI scanners have become increasingly common. However, these present the issue of biases in image-based measures due to scanner or site differences. To assess these biases…
View article: Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy Open
SARS-CoV-2 mRNA vaccination in healthy individuals generates effective immune protection against COVID-19. Little is known, however, about the SARS-CoV-2 mRNA vaccine-induced responses in immunosuppressed patients. We investigated inductio…
View article: An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability Open
Background Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may …
View article: Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial Open
Background: Upper extremity (UE) impairment is common with primary progressive multiple sclerosis (PPMS). Objective: This exploratory analysis examined the effects of ocrelizumab on confirmed progression (CP) and confirmed improvement (CI)…
View article: Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients Open
$\textbf{Objective:}$ To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. $\textbf{Me…